Table 3.
The oncologic outcomes of LDR brachytherapy using a definition of surgery (PSA >0.2 ng/mL)
| Number of patients | Procedure | Definition | Median follow-up | Outcomes | |
|---|---|---|---|---|---|
| Critz et al14 (2013) | 3546 | LDR + EBRT | 3 consecutive increase (Less than 5 years) Thereafter 0.2 ng/mL |
11 yr | 10-yr DFS Low: 93% Int: 74% High: 44% |
| Tanaka et al15 (2017) | 445 | LDR ± EBRT (n = 445) vs. IMRT (n = 165) | 0.2 ng/mL | 75 mo | 5-yr BCR-free rate LDR vs. IMRT Low: 77% vs. 38% P = 0.001 Int: 79% vs. 37% P < 0.001 High: 84% vs. 69% P < 0.001 |
| Morris et al16 (ASCENDE-RT) (2018) | 398 | DE-EBRT (n = 195) vs. LDR + EBRT (n = 188) | 0.2 ng/mL | 78 mo | 7-yr bPFS LDR vs. DE-EBRT Int: 91% vs. 40% High: 81% vs. 34% P < 0.001 |
| Tsumura et al17 (2022) | 428 | RP (n = 214) vs. LDR ± EBRT (n = 214) | 0.2 ng/mL | 96 mo | 8-yr BCR-free rate LDR vs. RP Int: 76% vs. 74% P = 0.642 |
| 302 | RP without PSM (n = 151) vs. LDR ± EBRT (n = 151) | 0.2 ng/mL | 96 mo | 8-yr BCR-free rate LDR vs. RP Int: 76% vs. 83% P = 0.136 |
BCR, biochemical recurrence; bPFS, biochemical progression-free survival; DE, dose escalated; DFS, disease-free survival; EBRT, external beam radiation therapy; High, high-risk; IMRT, intensity modulated radiation therapy; Int., intermediate-risk; LDR, low-dose-rate brachytherapy; Low, low-risk; PSM, positive surgical margin; RP, radical prostatectomy.